New York-based Ovid Therapeutics has appointed Dr Jerome Zeldis to its scientific advisory board.
Ovid is a privately-held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain.
Dr Zeldis has been noted for his successful experience in drug development and previously served as Celgene’s senior VP of clinical research and medical affairs.
Prior to joining Celgene in 1997, Dr Zeldis was associate director of clinical research at Sandoz Research Institute and director of medical development at Janssen Pharmaceutical Research Institute.
He said: “Ovid is pursuing an ambitious approach of tackling rare neurological diseases with significant unmet needs. With this goal, the company has assembled a world-class leadership and is employing a science-based approach to target new pathways that are involved in these diseases.
“I look forward to working closely with Ovid’s team.”
Jeremy Levin, CEO and chairman of Ovid, added: “We are delighted and privileged to welcome Jerry to our scientific advisory board.
“Jerry’s advice and insight will be extremely valuable as we enter the clinic.”